|
| [February 18, 2013] |
 |
Research and Markets: Portal Hypertension - Pipeline Review, H2 2012
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/wvdfww/portal)
has announced the addition of Global Markets Direct's new report "Portal
Hypertension - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H2
2012', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for
Portal Hypertension, complete with latest updates, and special features
on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Portal Hypertension.
Scope
- A snapshot of the global therapeutic scenario for Portal Hypertension.
- A review of the Portal Hypertension products uder development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Portal Hypertension pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to Buy
- Identify and understand important and diverse types of therapeutics
under development for Portal Hypertension.
- Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of
the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding
Portal Hypertension pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/wvdfww/portal
Source (News - Alert): Global Markets Direct

[ Back To Technology News's Homepage ]
|